Arthrosi Therapeutics, Inc.

📍 San Diego, United States👥 35 employees💰 Last funded Jun 2025
Pharmaceutical Manufacturing🌐 arthrosi.com
Website LinkedIn
Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Arthrosi Therapeutics, Inc.?
Arthrosi Therapeutics, Inc. has 1 investors on record on gritt.io.
When did Arthrosi Therapeutics, Inc. last raise funding?
The most recent investment in Arthrosi Therapeutics, Inc. recorded on gritt.io was in June 2025.
What industry is Arthrosi Therapeutics, Inc. in?
Arthrosi Therapeutics, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Arthrosi Therapeutics, Inc. based?
Arthrosi Therapeutics, Inc. is headquartered in San Diego, United States.